Meet the drug war’s latest creation: Cychlorphine

Another, more potent synthetic opioid has begun appearing in forensic laboratories: cychlorphine.

Authorities in several states and countries have recently detected it in the illicit drug supply. Unlike fentanyl or nitazenes, cychlorphine belongs to a different chemical family and can be synthesized using common industrial chemicals, many of which are not used in fentanyl synthesis. This makes it even harder for authorities to track or restrict using the familiar strategy of precursor controls.

If the pattern holds — as it has repeatedly over the past half-century — cychlorphine will not be the last, nor the most potent, new opioid to emerge from the cat-and-mouse game between drug prohibition and illicit innovation. This development shouldn’t surprise authorities.

The opioid crisis has followed a grim pattern for more than two decades. Each time policymakers tighten the screws on one drug, the illicit market shifts to something stronger, cheaper, more dangerous and easier to conceal. As prescription pain pills became harder to obtain, many users turned to heroin. When enforcement pressure disrupted heroin supply, traffickers moved to fentanyl. When fentanyl and its precursors drew the attention of regulators and law enforcement, chemists pivoted again — to nitazenes and other novel synthetic opioids.

Reports suggest cychlorphine began appearing only recently. Forensic monitoring systems first detected it in parts of Europe around 2024. By 2025 it showed up in drug-checking programs in Toronto and in seized drug samples in southwest Ohio. Since then, authorities have reported detections or related overdose deaths in places such as eastern Tennessee, central Kentucky and the Chicago area. Like many of the synthetic opioids that preceded it — including the nitazenes that began appearing in the illicit market a few years ago — cychlorphine often turns up not as a labeled product but mixed into counterfeit pills or polysubstance mixtures — another sign that traffickers are already experimenting with the next generation of synthetic drugs.

The idea that cychlorphine is simply a more powerful version of fentanyl is wrong. Fentanyl manufacturing became easier to track because its synthesis focuses on a small set of well-known, commercially available intermediates that regulators have learned to monitor. Even the more potent fentanyl analogs share much of fentanyl’s core structure, so the regulators’ lists remain useful.

With cychlorphine, however, all bets are off. Although cychlorphine and fentanyl share some recognizable structural elements, much of the molecule is different. As a result, the list of precursor chemicals used to track fentanyl production will be different from and less likely to be of help in identifying cychlorphine manufacturing.

Worse still, a structurally different opioid can still bind to the same brain receptor as morphine, but more tightly. Even the most experienced organic chemist could look at the structures of morphine and cychlorphine and see essentially no resemblance. This makes it extremely hard to predict what the next novel opioid will look like.

The emergence of a new generation of synthetic opioids might seem unrelated to antiviral or antibacterial resistance, but the analogy is fitting. Microbes respond to drugs that block replication by developing resistance. Chemists facing pressure from law enforcement and changing economic incentives adapt similarly. If law enforcement makes molecule X hard to produce, there will always be a molecule Y — real or imagined — ready to replace it.

This is the iron law of prohibition — the harder the enforcement, the harder the drug — functioning at the molecular level.

It is worth asking what we have gained from the massive effort required to tame fentanyl. Perhaps we have bought a temporary respite by suppressing one monster. But prohibition does not end the arms race — it accelerates it. And cychlorphine may simply be the latest creation of that policy.

Dr. Jeffrey A. Singer practices general surgery in Phoenix and is a senior fellow at the Cato Institute. His latest book is “Your Body, Your Health Care” (Cato Institute). Josh Bloom is director of chemical and pharmaceutical science at the American Council on Science and Health.

Copyright 2026 Nexstar Media Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

More Opinions - Healthcare News

Senate Democrats defeat amendment to require photo ID to vote

Montana Senate candidate says he will introduce bill to draft Graham if elected

Senate agrees to fund TSA and most of DHS, but not ICE

Judge asked to take Trump name off Kennedy Center

Trump disapproval highest in both terms: Fox News poll

House Democrats appear ready to back Senate DHS funding deal

Live updates: House navigates path to passing Senate DHS funding deal

Freedom Caucus slams Senate DHS deal, complicating path to swift passage

Are migrating Democrats turning Florida blue?

House Ethics panel finds 25 of 27 counts against Cherfilus-McCormick proven

How Trump lost the war with Iran 

Trump slams ‘terrible’ Fox News polls

Here are Iran’s 5 conditions for ending war after rejecting US ceasefire plan

First Democrats call for Cherfilus-McCormick to resign over ethics findings 

Cooper leads Whatley by 8 points in NC Senate race: Survey 

Trump’s order on birthright citizenship would harm millions, including ...

Diabetes drug metformin affects the brain, study finds: Here’s how

Trump says ‘military wanted’ White House ballroom: ‘That was supposed to ...

The Hill Podcasts – Morning Report

© The Hill